Download presentation
Presentation is loading. Please wait.
Published byΘέκλα Γεννάδιος Modified over 5 years ago
1
Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis
Yuka Makino, MS, Emiko Noguchi, MD, PhD, Noboru Takahashi, MD, PhD, Yuri Matsumoto, MS, Seita Kubo, MD, Takechiyo Yamada, MD, PhD, Yoshimasa Imoto, MD, Yumi Ito, MD, Yoko Osawa, MD, Masanao Shibasaki, MD, Kazuhiko Uchida, PhD, Kohji Meno, PhD, Hideaki Suzuki, BA, Kimihiro Okubo, MD, PhD, Tadao Arinami, MD, PhD, Shigeharu Fujieda, MD, PhD Journal of Allergy and Clinical Immunology Volume 126, Issue 6, Pages e5 (December 2010) DOI: /j.jaci Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
2
Fig 1 Upregulated and downregulated proteins by 2-DE analysis. Upregulated or downregulated protein spots that were altered in the actively treated and placebo-treated groups are marked with circles. The spot numbers correspond to the numbers in Table II. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
3
Fig 2 DeCyder differential analysis software output. Quantitative assessments of protein spots were obtained with the DeCyder-based quantization software. The y-axis represents the standardized log abundance of protein expression. The graphical data show the abundance of the protein corresponding to spot 10 in the actively treated group. The spot number corresponds to the number in Table II. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
4
Fig 3 Results of the network analysis by Ingenuity pathways analysis. The complement factor C4A, apoA-IV, and transthyretin are shown in red. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
5
Fig 4 Correlation of the fold change in apoA-IV with the SMS. A statistically significant correlation was observed between the levels of apoA-IV and the SMS (r = –0.635; P = .011 in the actively treated group. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
6
Fig 5 Histamine release from basophils with or without apoA-IV. The graph shows the histamine release rate from the basophils of SAR patients with or without apoA-IV. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
7
An example of nano-HPLC sample separation and MALDI-TOF/TOF analysis (spot 10). A, An example of a chromatograph of nano-HPLC. The y-axis represents intensity, which shows the relative abundance of the separated peptide at each separation time. B, An example of MALDI-TOF/TOF analysis. The MS/MS data show underlined amino acid sequences, which form part of apoA-IV. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
8
Western blotting with apoA-IV–specific antibody
Western blotting with apoA-IV–specific antibody. A, 2-DE image of the total protein stained with Deep Purple total protein stain. B, 2-DE image of the total protein merged with the image detected with the apoA-IV–specific antibody. The arrow indicates the spot corresponding to apoA-IV. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
9
Representative Western blot image of apoA-IV in actively treated and placebo-treated groups.
Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.